TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04258007

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Reversal Neostigmine
Description: Patients will receive 0.02 mg/ kg atropine and 0.04 mg/ kg neostigmine following observing the second response on stimulating the ulnar nerve on the TOF watch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reversal Sugammadex
Description: Interventional Arm Patients undergoing cardiac catheterization will receive sugammadex 4 mg/ kg when the T2 is observed on the TOF watch
Study: NCT02481596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REACH + FAMS
Description: The intervention consists of REACH individual-focused text messaging, plus family-focused phone coaching sessions, goal-focused text messaging, and the option to invite a family member/support person to receive text messages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REACH
Description: The intervention consists of daily text messaging tailored to user's individual barriers to medication adherence, plus text messaging targeting other self-care behaviors (see NCT02409329).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REACH
Description: The intervention consists of daily text messaging tailored to user's individual barriers to medication adherence, plus text messaging targeting other self-care behaviors (see NCT02409329).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Helpline & A1c results
Description: Participants complete all study assessments, receive text messages advising how to access study A1c results, and have access to a helpline for study- or diabetes medication-related questions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Helpline & A1c results
Description: Participants complete all study assessments, receive text messages advising how to access study A1c results, and have access to a helpline for study- or diabetes medication-related questions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Helpline & A1c results
Description: Participants complete all study assessments, receive text messages advising how to access study A1c results, and have access to a helpline for study- or diabetes medication-related questions.
Study: NCT02131246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Subjects will receive a single dose of either Faster-acting insulin aspart or NovoRapid® at a predefined fixed dose level in connection to intake of a standardised meal. Administered subcutaneously (s.c., under the skin)
Study: NCT03427346

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic mucosal resection
Description: Endoscopic resection is carried out using a double-channel scope. The lesion borders are marked with a coagulator. Saline liquid and sometimes epinephrine are injected into the submucosal layer to swell the area containing the lesion and elucidate the markings. The resected mucosa is lifted, then trapped and strangulated with a snare, and subsequently resected by electrocautery. Another method of EMR employs the use of a clear cap and prelooped snare inside the cap. After insertion, the cap is placed on the lesion and the mucosa containing the lesion is drawn up inside the cap by aspiration. The mucosa is caught by the snare and strangulated, and finally resected by electrocautery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic submucosal dissection
Description: After circumferential cutting of the surrounding mucosa of the lesion, fluid is injected into the submucosa to elevate the lesion from the muscle layer, and the connective tissue of the submucosa beneath the lesion is dissected subsequently.
Study: NCT03185650

Intervention type: DEVICE
Group type: OTHER
Intervention: tPAD Device
Description: A novel, transnasal aerosol generator

Intervention type: DEVICE
Group type: OTHER
Intervention: tPAD Device
Description: A novel, transnasal aerosol generator

Intervention type: DEVICE
Group type: OTHER
Intervention: PARI LC Star Nebulizer
Description: Standard oral nebulizer

Intervention type: DEVICE
Group type: OTHER
Intervention: PARI LC Star Nebulizer
Description: Standard oral nebulizer
Study: NCT01989741

Intervention type: OTHER
Group type: OTHER
Intervention: Sleep restriction
Description: 4 hours sleep by night during one week
Study: NCT00848887

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted and un-adjuvanted influenza vaccines
Description: 16 different formulations of trivalent influenza vaccine and 1 marketed influenza vaccine comparator.
Study: NCT03967535

Intervention type: DEVICE
Intervention: MRI Brain Imaging
Description: Up to two Magnetic Resonance Imaging (MRI) scan sessions will be done, altogether totaling just under 3 hours of scanning. MR scanners measure brain anatomy and activity using very strong magnets. No X-rays or radiation are involved.

Intervention type: DEVICE
Intervention: MRI Brain Imaging
Description: Up to two Magnetic Resonance Imaging (MRI) scan sessions will be done, altogether totaling just under 3 hours of scanning. MR scanners measure brain anatomy and activity using very strong magnets. No X-rays or radiation are involved.

Intervention type: BEHAVIORAL
Intervention: Mental Health Assessment and Computerized Cognitive Test
Description: Participants will be asked to complete questionnaires and will be asked questions that address a broad range of personal life experiences involving social, occupational, domestic, and other behaviors.

Intervention type: BEHAVIORAL
Intervention: Mental Health Assessment and Computerized Cognitive Test
Description: Participants will be asked to complete questionnaires and will be asked questions that address a broad range of personal life experiences involving social, occupational, domestic, and other behaviors.
Study: NCT04390295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824
Description: Once daily, 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824
Description: Once daily, 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Three times daily, 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Three times daily, 52 weeks
Study: NCT03481816

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-071; adenoviral PSA vaccine
Description: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.
Study: NCT02789553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: First starch meal then meal with glucose syrup
Description: Before bypass surgery, patients will take randomized meal. One day a starch meal and another day a glucose syrup meal. 3 months after surgery, they will take these 2 randomized meal again, one day the first one, and the day after the other one.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: First starch meal then meal with glucose syrup
Description: Before bypass surgery, patients will take randomized meal. One day a starch meal and another day a glucose syrup meal. 3 months after surgery, they will take these 2 randomized meal again, one day the first one, and the day after the other one.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: First meal with glucose syrup then starch meal
Description: Before bypass surgery, patients will take randomized meal. One day a meal with glucose syrup and another day a starch meal. 3 months after surgery, they will take these 2 randomized meal again, one day the first one, and the day after the other one.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: First meal with glucose syrup then starch meal
Description: Before bypass surgery, patients will take randomized meal. One day a meal with glucose syrup and another day a starch meal. 3 months after surgery, they will take these 2 randomized meal again, one day the first one, and the day after the other one.
Study: NCT03468595

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasonic (Piezon Master 700) performed with Listerine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasonic (Piezon Master 700) performed with CHX

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasonic (Piezon Master 700) performed with serum
Study: NCT00485420

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet based disease management program
Description: Usual Care is augmented with internet-based education, self-monitoring and clinician monitoring

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internet based disease management program
Description: Usual Care is augmented with internet-based education, self-monitoring and clinician monitoring
Study: NCT00439595

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemocue 210 meter
Description: Diagnostic device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Copack HBCS
Study: NCT01034501

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham procedure
Description: non activated laser tip

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: photodynamic therapy
Description: photodynamic therapy 660 nm,40 mW,60 Hz
Study: NCT02708316

Intervention type: GENETIC
Intervention: sequencing faecal metagenome
Description: sequencing faecal metagenome is not the intervention measure.It is the observational method for investigators to detect the component of faecal microorganism.

Intervention type: GENETIC
Intervention: sequencing faecal metagenome
Description: sequencing faecal metagenome is not the intervention measure.It is the observational method for investigators to detect the component of faecal microorganism.
Study: NCT02649920

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical ripening balloon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone
Study: NCT00595296

Intervention type: DEVICE
Intervention: GeneSearch™ Breast Lymph Node (BLN) Assay
Description: The GeneSearch™ BLN Assay is a real time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay that detects the presence of breast tumor cell metastasis in lymph nodes through the detection of gene expression markers present in breast tissue, but not in nodal tissue (cell type specific messenger RNA).
Study: NCT03930381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ASTHMAXcel App
Description: ASTHMAXcel includes interactive games, educational videos, quizzes and personalized feedback to teach different aspects of asthma management.
Study: NCT03551834

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional scleral patch graft glaucoma implantation
Description: conventional AGV implantation by using scleral patch graft to cover the tube and prevent tube exposure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: New surgical method (short tunnel small flap technique)
Description: a novel technique named short tunnel small flap (STSF) by tunneling the sclera to pass the AGV tube without using scleral patch graft.
Study: NCT01367379

Intervention type: PROCEDURE
Intervention: 24 hour EKG and blood pressure monitor
Description: All subjects will have non-invasive 24 hour EKG and 24 hour EKG monitoring for 24 hours.

Intervention type: OTHER
Intervention: Blood and urine sampling
Description: Right before and after the duty loading, all subjects will have blood samplings, including CRP, WBC, IL-6, Fibrinogen, insulin, IL-6, Procalcitonin, TNF-alfa, catecholamine level. Right after the duty loading, all subjects will have urine samplings for cortisol and catecholamine level.(blood : 15CC/time and 2\~4 times/month)
Study: NCT03326635

Intervention type: OTHER
Intervention: Frailty in elderly (≥70 y) patients in ICU
Description: Determine the prevalence of frailty in elderly patients (≥ 70 year old) in a group of French ICUs. The frailty is measured by a score (Fried score) at the admission of the patient

Intervention type: OTHER
Intervention: Frailty in elderly (≥70 y) patients in ICU
Description: Determine the prevalence of frailty in elderly patients (≥ 70 year old) in a group of French ICUs. The frailty is measured by a score (Fried score) at the admission of the patient
Study: NCT00481455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panzem NCD
Description: 2000 mg q8h, continuous dosing in 28 day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Fixed dose
Study: NCT03041324

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB-913
Description: Single dose of each of the 3 components of SB-913: ZFN1, ZFN2 and hIDS Donor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB-913
Description: Single dose of each of the 3 components of SB-913: ZFN1, ZFN2 and hIDS Donor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB-913
Description: Single dose of each of the 3 components of SB-913: ZFN1, ZFN2 and hIDS Donor
Study: NCT04284995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RUC-4 Compound
Description: All patients will receive a single subcutaneous dose of RUC-4 in the Cardiac Catheterization Lab (CCL) before coronary angiography/percutaneous coronary intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RUC-4 Compound
Description: All patients will receive a single subcutaneous dose of RUC-4 in the Cardiac Catheterization Lab (CCL) before coronary angiography/percutaneous coronary intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RUC-4 Compound
Description: All patients will receive a single subcutaneous dose of RUC-4 in the Cardiac Catheterization Lab (CCL) before coronary angiography/percutaneous coronary intervention.
Study: NCT01622686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PictureRx medication label
Description: Reformatted medication labels that adhere to current best practices for label design and also include illustrations
Study: NCT04751539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AND017 single dose
Description: AND017 administrated as oral single-dose on Day 1 in Part A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AND017 multiple dose
Description: AND017 administrated once daily from Day 1 to Day 10 in Part B

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administrated once on Day 1 in Part A or daily from Day 1 to Day 10 in Part B
Study: NCT03761680

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MEDPass mode of administration
Description: Allocation of 50 ml of ONS four times per day distributed with the medication rounds

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: Patients receive ONS between meals or at their request as usual
Study: NCT02543619

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Injection technique
Description: One group received Gow-Gates technique and the other group received Infra Alveolar Nerve Block technique for their failed first one anesthesia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Injection technique
Description: One group received Gow-Gates technique and the other group received Infra Alveolar Nerve Block technique for their failed first one anesthesia
Study: NCT04629417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart Physiotherapy Activity Recognition System (SPARS)
Description: Wearable smart watch that records inertial data such as (accelerometer, gyroscope magnetometer) while patients are performing physiotherapy exercises.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smart Physiotherapy Activity Recognition System (SPARS)
Description: Wearable smart watch that records inertial data such as (accelerometer, gyroscope magnetometer) while patients are performing physiotherapy exercises.
Study: NCT03349008

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Entecavir
Description: Glycyrrhizin for the treatment of patients with chronic hepatitis B combined with entecavir-based

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Glycyrrhizin for the treatment of patients with chronic hepatitis B combined with entecavir-based

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Isoglycyrrhizinate
Description: Magnesium Isoglycyrrhizinate Injection treat for two weeks with entecavir-based

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diammonium Glycyrrhizinate
Description: Diammonium Glycyrrhizinate for oral after Magnesium Isoglycyrrhizinate Injection treatment with entecavir-based

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium Isoglycyrrhizinate Placebo
Description: Magnesium Isoglycyrrhizinate Injection Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diammonium Glycyrrhizinate Placebo
Description: Diammonium Glycyrrhizinate Enteric-coated Capsules Placebo
Study: NCT03958123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 μg cebranopadol
Description: Encapsulated 100 μg cebranopadol tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 μg cebranopadol
Description: Encapsulated 200 μg cebranopadol tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 μg cebranopadol
Description: Encapsulated 200 μg cebranopadol tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 μg cebranopadol
Description: Encapsulated 400 μg cebranopadol tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 μg cebranopadol
Description: Encapsulated 400 μg cebranopadol tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to cebranopadol encapsulated tablets
Description: Matching placebo to cebranopadol encapsulated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to cebranopadol encapsulated tablets
Description: Matching placebo to cebranopadol encapsulated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to cebranopadol encapsulated tablets
Description: Matching placebo to cebranopadol encapsulated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to cebranopadol encapsulated tablets
Description: Matching placebo to cebranopadol encapsulated tablet.
Study: NCT03481816

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-071; adenoviral PSA vaccine
Description: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061; adenoviral MUC1 vaccine
Description: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061; adenoviral MUC1 vaccine
Description: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051; adenoviral brachyury vaccine
Description: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051; adenoviral brachyury vaccine
Description: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.
Study: NCT03958123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg Moxifloxacin
Description: Encapsulated 400 mg moxifloxacin tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg Moxifloxacin
Description: Encapsulated 400 mg moxifloxacin tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to moxifloxacin encapsulated tablets
Description: Matching placebo to moxifloxacin (400 mg) encapsulated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to moxifloxacin encapsulated tablets
Description: Matching placebo to moxifloxacin (400 mg) encapsulated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to moxifloxacin encapsulated tablets
Description: Matching placebo to moxifloxacin (400 mg) encapsulated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to moxifloxacin encapsulated tablets
Description: Matching placebo to moxifloxacin (400 mg) encapsulated tablet.
Study: NCT03934320

Intervention type: OTHER
Group type: OTHER
Intervention: FAMCAT
Description: The intervention is a computer-based software algorithm (FAMCAT) for use in general practice with a family history questionnaire.
Study: NCT01688570

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: duloxetine
Description: Single dose, orally (pill), 30 mg, taken 6 hours prior to start of the testing session. Subjects will only take a single dose of duloxetine once.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyproheptadine
Description: Single dose, orally, 8 mg, 6 hours prior to the start of the respective testing session. Subjects will take a single dose of cyproheptadine once.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose, orally, 6 hours prior to the start of the respective testing session. Subjects take a single dose once.
Study: NCT00475592

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal Capsule Endoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Upper Gastrointestinal Endoscopy
Study: NCT03497273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Itacitinib administered orally once daily at the protocol-defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: Either oral prednisolone or intravenous methylprednisolone at the investigator's discretion.
Study: NCT00769353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary and Secondary Coping Enhancement Training
Description: A cognitive behavioral therapy designed to help individuals cope with physical illness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Non-directive Therapy
Description: A non-structured therapy designed to provide a supportive atmosphere in which individuals may discuss concerns and process events in their lives